Spikevax Bivalent Original/Omicron Ba.1

Spikevax Bivalent Original/Omicron Ba.1 is a COVID-19 vaccine designed to target both the original and Omicron Ba.1 variants. It is administered intramuscularly and helps provide protection against COVID-19 infection and severe outcomes. This vaccine is authorized for use in the EU and follows standard immunization protocols.

Spikevax Bivalent Original/Omicron Ba.1 is used for active immunization against COVID-19 caused by SARS-CoV-2 and its variants, including Omicron Ba.1. It is intended for individuals aged 12 and older to reduce the risk of infection and severe disease. The vaccine is part of public health efforts to control the spread of COVID-19. It does not treat existing infections but aims to prevent future illness.

After administration, Spikevax Bivalent Original/Omicron Ba.1 stimulates the immune system to produce antibodies against SARS-CoV-2. Common effects include temporary pain at the injection site, fatigue, headache, and mild fever. These effects are typically mild to moderate and resolve within a few days. The vaccine does not cause COVID-19 infection but may produce immune response symptoms.

Spikevax Bivalent Original/Omicron Ba.1 should be handled and administered by trained healthcare professionals. Individuals with a history of severe allergic reactions to vaccine components should consult a healthcare provider before receiving the vaccine. It is important to report any adverse reactions to a medical professional. The vaccine should be stored at recommended temperatures to maintain efficacy.

Spikevax Bivalent Original/Omicron Ba.1 may interact with immunosuppressive therapies, potentially reducing its effectiveness. No significant interactions with other medications have been established, but it is recommended to inform healthcare providers about all current medications. Alcohol consumption does not directly interact with the vaccine but may impact overall health. Live vaccines should not be administered concurrently without medical advice.